Fredun Pharma Reappoints Internal & Cost Auditors for FY 2026-27

Fredun Pharmaceuticals Ltd re-appointed M/s. Nikhil Maniar & Associates as Internal Auditor and M/s. Joshi Apte & Associates as Cost Auditor for the financial year 2026-2027. This decision was made during the Board of Directors meeting held on May 25, 2026, where the board also approved the audited financial results for the quarter and financial year ended March 31, 2026, recommended a final dividend of 7% (₹0.70 per share), approved an increase in authorized share capital, and approved the issuance of bonus shares in the ratio of 2:1.